Study On The Expression Of CHD1L,TIAM1,TIP30 And GRIM19 Genes In Endometrial Carcinoma

Objective:To investigate the expression,clinical significance and prognostic effect of CHD1L,TIAM1,TIP30 and GRIM19 in type I endometrial carcinoma.Methods:The expression levels of CHD1L,TIAM1,TIP30 and GRIM19 in 70 cases of type I endometrial carcinoma,24 cases of endometrial dysplasia,20 cases of endometrial hyperplasia without dysplasia,and 28 cases of normal endometrial tissue were detected by immunohistochemistry.The relationship between its expression in type I endometrial carcinoma and age,degree of differentiation,surgical pathological stage,depth of muscular invasion,lymph node metastasis,vascular invasion,menopause,complicated hypertension,birth and survival time was analyzed.SPSS 26.0 statistical software was used for statistical analysis.Results:1.The proto-oncogene CHD1L was mainly expressed in the nucleus and cytoplasm of type I endometrial carcinoma,and the expression level of CHD1L in normal endometrium,endometrial hyperplasia without atypical hyperplasia,endometrial atypical hyperplasia and type I endometrial carcinoma was gradually increased（χ²=20.326,P=0.000;P<0.05）;The expression level of CHD1L in cancer group was significantly higher than that in normal group and hyperplasia without atypical hyperplasia,while that in atypical hyperplasia group was significantly higher than that in normal group(χ_{cancer/normal}²=14.704,Pcancer/normal=0.000;χ2cancer/hyperplasia=9.029,Pcancer/hyperplasia=0.003;χ2atypical/norm _al=3.964,P_{atypical/normal}=0.046,P<0.05),the difference was statistically significant.There were no significant differences between atypical hyperplasia group and non-atypical hyperplasia group,（χ²=1.956,P=0.162,P>0.05）.In 70 cases of type I endometrial carcinoma,the high expression rate of CHD1L protein was significantly correlated with surgical pathological stage,depth of muscular invasion,lymph node metastasis and vascular invasion（χ²=6.039,8.556,9.989,11.237,P=0.014,0.003,0.002,0.001,P<0.05）,the difference was statistically significant;There were no significant difference in age,degree of differentiation,menopause,hypertension and birth rate（χ²=2.100,1.897,0.025,0.483,0.025,P=0.147,0.168,0.874,0.487,0.873,P>0.05）.2.TIAM1 was mainly located in the cytoplasm of type I endometrial carcinoma,and the expression level of CHD1L in normal endometrium,endometrial hyperplasia without atypical hyperplasia,endometrial atypical hyperplasia and type I endometrial carcinoma was gradually increased（χ²=18.069,P=0.000,P<0.05）.The high expression rate of TIAM1 in cancer group was significantly higher than that in normal group and hyperplasia without atypical hyperplasia,while that in atypical hyperplasia group was significantly higher than that in normal group(χ2cancer/normal=14.107,Pcancer/normal=0.000;χ2cancer/hyperplasia=8.107,P_{cancer/hyperplasia}=0.004;χ_{atypical/normal}²=6.031,P_{atypical/normal}=0.014,P<0.05),the difference was statistically significant.There were no significant difference between atypical hyperplasia group and non-atypical hyperplasia group（χ²=3.300,P=0.069,P>0.05）.In 70 cases of type I endometrial carcinoma,the high expression rate of TIAM1 protein was significantly correlated with the degree of differentiation,depth of muscular invasion and lymph node metastasis（χ²=7.536,5.800,4.201,P=0.006,0.016,0.004,P<0.05）.There were no significant difference in age,surgical pathological stage,vascular infiltration,menopause,hypertension and birth rate（χ²=0.003,2.051,0.208,0.012,0.072,0.000,P=0.956,0.152,0.648,0.912,0.788,1.000,P>0.05）.3.Oncosuppressor gene TIP30 was mainly located in the cytoplasm of type I endometrial carcinoma.The expression level of CHD1L in normal endometrium,endometrial hyperplasia without atypical hyperplasia,endometrial atypical hyperplasia and type I endometrial carcinoma was gradually decreased（χ²=20.204,P=0.000,P<0.05）.The high expression rate of TIP30 in cancer group was significantly lower than that in normal group and non-atypical hyperplasia group,and that in atypical hyperplasia group was significantly lower than that in normal group(χ²cancer/normal=15.076,Pcancer/normal=0.000;χ²cancer/hyperplasia=7.874,Pcancer/_hyperplasia=0.005;χ_{atypical/normal}²=7.998,P_{atypical/normal}=0.006,P<0.05),the difference was statistically significant.There were no significant difference between atypical hyperplasia group and non-atypical hyperplasia group（χ²=2.184,P=0.139,P>0.05）.（3）In 70 cases of type I endometrial carcinoma,TIP30 expression was significantly correlated with age,degree of differentiation,surgical pathological stage,lymph node metastasis and vascular invasion（χ²=4.598,4.781,7.664,5.481,12.173;P=0.032,0.029,0.006,0.019,0.000;P<0.05）,but there were no significant differences with the depth of muscular invasion,menopause,hypertension,and birth rate（χ²=3.420,1.776,0.591,1.261,P=0.064,0.183,0.442,0.261,P>0.05）.4.Tumor metastasis suppressor gene GRIM19 was mainly located in the cytoplasm of type I endometrial carcinoma,The expression level of CHD1L in normal endometrium,endometrial hyperplasia without atypical hyperplasia,endometrial atypical hyperplasia and type I endometrial carcinoma was gradually decreased（χ²=24.977,P=0.000,P<0.05）.The high expression rate of GRIM19 in cancer group was significantly lower than that in normal group and hyperplasia without atypical hyperplasia group,while that in atypical hyperplasia group was significantly lower than that in normal group(χ_{cancer/normal}²=27.470,P_{cancer/normal}=0.000;χ²=7.347,P=0.007;χ_{atypical/normal}²=7.518,P_{atypical/normal}=0.006,P<0.05),the difference was statistically significant.There were no significant difference between atypical hyperplasia group and non-atypical hyperplasia group（χ²=1.605,P=0.205,P>0.05）.In 70 cases of type I endometrial carcinoma,the high expression rate of GRIM19protein was significantly correlated with the degree of differentiation,surgical pathological stage,depth of muscular invasion,lymph node metastasis,vascular invasion and hypertension（χ²=8.239,5.389,4.970,6.077,6.965,6.266,P=0.004,0.020,0.026,0.014,0.008,0.012,P<0.05）,but there was no significant difference with age,menopause or birth（χ²=0.598,0.000,0.313,P=0.439,0.988,0.576,P>0.05）.5.Spearman rank correlation test showed that TIP30 protein expression was negatively correlated with CHD1L in type I endometrial carcinoma（r=-0.315,P=0.008,P<0.05）.The expression of TIAM1 was negatively correlated with GRIM19（r=-0.373,P=0.001,P<0.05）.6.70 patients with type I endometrial carcinoma had a close correlation with pathological stage,depth of muscularinvasion,lymph node metastasis,vascular metastasis,CHD1L expression,GRIM19expression and TIP30 expression（χ²=32.906,6.622,10.987,46.767,6.462,5.918,10.524,P=0.000,0.016,0.001,0.000,0.011,0.015,0.001,P<0.05）.There were no significant differences with age,differentiation degree,menopause,hypertension and TIAM1 expression（χ²=0.052,1.680,0.001,0.736,0.072,P=0.820,0.195,0.975,0.391,0.788,P>0.05）.7.Conclusion:CHD1L,TIAM1,TIP30 and GRIM19 are involved in the malignant transformation of type I endometrial carcinoma,CHD1L and TIAM1 promote the development of endometrial carcinoma,TIP30and GRIM19 inhibit the malignant transformation of endometrial carcinoma.Among them,CHD1L,TIP30 and GRIM19 may also be important indicators affecting the prognosis of endometrial cancer.